Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Biodexa Pharmaceuticals (NASDAQ:BDRX) to a sell rating in a report issued on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 15th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Down 7.1%

Biodexa Pharmaceuticals stock opened at $2.63 on Friday. The firm’s fifty day moving average price is $5.24 and its 200-day moving average price is $6.81. Biodexa Pharmaceuticals has a fifty-two week low of $2.55 and a fifty-two week high of $92.00.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.